Long-Term Excess Mortality for Survivors of Non-small Cell Lung Cancer in the Netherlands-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-Term Excess Mortality for Survivors of Non-small Cell Lung Cancer in the Netherlands

Published:2012-03 Issue:3 Volume:7 Page:496-502
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Janssen-Heijnen Maryska L.,van Steenbergen Liza N.,Steyerberg Ewout,Visser Otto,De Ruysscher Dirk K.,Groen Harry J.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. The changing epidemiology of lung cancer in Europe;Janssen-Heijnen;Lung Cancer,2003

2. Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark;Skuladottir;J Clin Oncol,2003

3. People's perceptions of cancer survivability: implications for oncologists;Donovan;Lancet Oncol,2006

4. Prognosis for long-term survivors of cancer;Janssen-Heijnen;Ann Oncol,2007

5. Completeness of cancer registration in Limburg, The Netherlands;Schouten;Int J Epidemiol,1993

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the Performance of Alternative Methods for Estimating Long-Term Survival Benefit of Immuno-oncology Therapies;Value in Health;2024-02

2. Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective;Frontiers in Public Health;2023-09-29

3. Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence;Lung Cancer Management;2023-07-12

4. Cost–effectiveness of adjuvant atezolizumab for patients with stage II–IIIA PD-L1+ non-small-cell lung cancer;Immunotherapy;2023-06

5. Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective;Lung Cancer;2023-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3